Good for us morning, joining and today. thank you
who responsibilities conducted recognize for and role. team Genzyme, ground our more I’d the into running. Before I and us to He comes Therapeutics. joined and Marc Nancy Chief CRISPR than a Concert search industry, to Stuart, and most like Also Financial the Marc biotechnology including his to XX of hit rEVO to welcome is discussion, addition a ably jump XX-year pipeline while Concert at within years I’d Becker Officer. our with the financial CFO January expertise our to as in has like we assumes thank great early recently
branded adjunctive night risk for compounds. our deuterated was our with of the candidate D-serine, to that to is new recently, amino it selection strategic our the branded another to its of our deuterated deuterium profile last considerations in enhancing one on and proprietary of candidate. compounds of technology. endogenous new process, studies by differs to our We’ve was greatly the and D-serine, worked of non-branded important team patient improve that demonstrated of provide can the neurotransmitter. In is profile versatility us our an consisted in pipeline clinical the both Most diligently potential we has schizophrenia. analogs our -- of is preclinical announced pipeline treatment creatively CTP-XXX, thereby compounds. applying advantage in CTP-XXX a pipeline, for balance as development an analog to technology significant significantly and great benefits Moving a safety which acid example is deuterium our expand pipeline
on call. We will go CTP-XXX on into later further this details
Let new candidate. very me our that we say excited pipeline are about opportunity with this
continues in turn let Alzheimer's more alopecia being CTP-XXX not candidates. plans our In our areata AVP-XXX not alopecia Phase CTP-XXX Now the develop or X. for our made inhibitor the to for to Board Appeals to Patent decision CTP-XXX for advance agitation, and for does to impact against highlight I’d by developed some me developments to proceeding January, moderate and decision This PGR severe Incyte. Institute Trial areata. like in is recent which JAK advanced Avanir. product
arguments patents that invalid. PTAB's validity of Court addition, Incyte's not Federal patent challenging we’ve we strong believe continue from in time, a later prohibit the us is to that does Incyte's In decision at and
milligram An of twice-daily As Independent for safety planned study cohort. milligrams completed a weeks interim the least assessment to XX evaluate Committee X sequentially designed milligrams Monitoring CTP-XXX at placebo after X compared weeks. four reminder, two Data is its the X and doses, to dosing of in
closer XXXX. DMC As milligram X year-end us data as milligram cohorts cohort important that we underway and is proceed by step the X expected, with bringing reporting recommended trial an enrollment the the the of to planned we on and X
moving for forward that priority Concert. strong as actively happy areata top this patient to the has say CTP-XXX I'm the are Also for trial among alopecia a the We been community. enthusiasm
for and that on development their facilitating serious designation existing development Fast-Track opportunity positive FDA, potential is severe drug Another an of supporting therapies for for announced earlier CTP-XXX for this standard areata. process. the mechanistic It diseases early communications or been we is which to quarter, for there and has improve Fast-track provides reserved with care. moderate designation the new clinical granted was it in review frequent evidence significantly alopecia more
that We FDA develop XXX. significant alopecia view with and with we is agrees areata look a process to that an we pleased disease FDA serious are need active our unmet forward with as productive and a very
due the in Avanir that stated X AVP-XXX, to dementia. to treatment U.S support to and XXXX Turning expected agitation in X has April is clinical AVP-XXX two intended the XXXX, Avanir currently of Phase trials complete studies be Phase are December Alzheimer's for and/or to evaluating registration ongoing respectively.
and the program that very We gratifying will global realize of support its XXX registration. of part growing to step clinical with that look alopecia portfolio invest continues late in agitation XXX stage an areata, it's candidates, potential. and creates platform that important in This also particular we that for an we’re to development believe our year. Phase of robust newest drug X for bigger take for encouraged position at development additional is Avanir are conducting U.S to provide AVP-XXX deuterium past picture how our deuterium commercial they’re help a this outside during candidate further CTP-XXX Alzheimer's pleased of value a But It's and and for our us CTP-XXX schizophrenia. the Avanir to for back update also
now ago, we XXXX. cystic Pharmaceuticals Vertex we into were CTP-XXX X weeks including a combination few the data this example VX-XXX Phase created of excited prime a that was their half they in with fibrosis known in pending the generate treatment advance year to will timeframe. deal Vertex short see first later Our as additional remarkably to for A plans of a triple CTP-XXX announced value
you potential development Concert based recall, significant future milestone on Vertex's XXX. of As may pre-commercial has
On approach denial our was win the the for challenging properties. patent side, Incyte’s proprietary Deuterium CTP-XXX not does PTAB's an October. modification petition of improve important last drug our patent always
the for The our does criteria it deuterated satisfying our to have CTP-XXX on XXX awarded when XXX fits warranted. to our exciting important pipeline drugs as PTO CTP-XXX, patent. approved with business see our us for validity next in has execution our led of to that in have our our in positive These identifying and over strategy led development patent it is us However, candidate. clinical the patents point PTAB provide expanding allowed today. as benefit has as well of They’ve overall an new protection on us U.S candidate ongoing was we the [technical candidates turn and to key difficulty] our CTP-XXX. focus next developments
wanted of to explore deuterium modification a efficacy need. we has compound important First, of medical evidence an non-branded well for understood that
to that encumbered human of safety dosing proof-of-concept. supporting a compound been substantial performance. important clinical studies. modification as identified has deuterium mechanistic has wanted foundation improvements by But clinical we which in that shortcomings potential a compounds D-serine the and have Second, provide preclinical We clinical limited
And before substitution game detail. window, could the suggests a Our our imparts compound. turn greatly program improved a in this following be strongly the Marc will to call from of point, the we CTP-XXX that deuterium therapeutic which results more At Jim preclinical let selective call discuss financial questions. the over changer this review to me data use to open XXXX that
